Cardinal Health (CAH) Stock
US healthcare distributor of drugs and medical products. Here's the price, business snapshot, and what's worth knowing about Cardinal Health in August 2026.
Cardinal Health, Inc. (CAH) is a major US healthcare services and products company, with a market capitalisation near $37.7 billion. It operates large-scale pharmaceutical distribution and supplies medical-surgical products to hospitals, pharmacies and clinics, while also developing higher‑margin device and services offerings. Investors should know the business combines high-volume, low-margin distribution with targeted growth in medical products, so operational efficiency, inventory management and contract terms are key profit levers. The company faces sector-specific risks including reimbursement pressure, hospital budget cycles, regulatory scrutiny and strong competition from peers. Recent strategic emphasis has been on margin improvement, specialty products and supply-chain resilience, though execution and healthcare demand trends will matter. This is general educational information, not personalised advice; values can rise or fall and past performance is no guarantee of future results. Consider how exposure to healthcare distribution fits your risk tolerance and investment horizon before acting.
Why It’s Moving
Cardinal Health edges lower as analysts see only modest downside and limited near-term catalysts.
- Analysts are flagging only a slight downside because Cardinal Health’s valuation sits near fair value, with one model putting the probability-weighted estimate about 2% below the current share price.
- The bearish case is tied less to a near-term shock and more to structural pressure in healthcare distribution, where reimbursement and channel disintermediation could compress margins over time.
- At the same time, analyst views remain split rather than broadly negative, which has kept the stock in a cautious range instead of a sharp trend move.
Cardinal Health edges lower as analysts see only modest downside and limited near-term catalysts.
- Analysts are flagging only a slight downside because Cardinal Health’s valuation sits near fair value, with one model putting the probability-weighted estimate about 2% below the current share price.
- The bearish case is tied less to a near-term shock and more to structural pressure in healthcare distribution, where reimbursement and channel disintermediation could compress margins over time.
- At the same time, analyst views remain split rather than broadly negative, which has kept the stock in a cautious range instead of a sharp trend move.
When is the next earnings date for CARDINAL HEALTH INC (CAH)?
Cardinal Health (CAH) is expected to report next on August 11, 2026, before the market opens. The release will cover the fiscal quarter ending June 2026, which is the company’s fiscal fourth quarter. Some estimates also place the date within the August 11–17 window, but the most specific current expectation is August 11, 2026.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health’s stock, expecting it to rise towards a higher target price.
Financial Health
Cardinal Health is generating decent revenue and cash flow, but has a low profit margin.
Dividend
Cardinal Health's low dividend yield of 0.77% may not appeal to dividend-focused investors. If you invested $1000 you would be paid $7.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring CAH
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketDefensive Equities | Risks in a Slowing Labour Market
After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published: 9 March 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketDow Record Rally: What's Next for Value Stocks?
The Dow Jones Industrial Average reached a historic high, closing above 48,000, fueled by the end of a government shutdown and a market rotation into value stocks. This shift suggests an investment opportunity in the outperforming healthcare and financial sectors, which are leading the charge.
Published: 13 November 2025
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.